Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
**SNG100** is an investigational topical cream developed by Seanergy Dermatology for moderate atopic dermatitis. It is a proprietary formulation of **hydrocortisone 1%** in an SNG vehicle containing sulphated polysaccharides derived from the red microalga *Porphyridium cruentum*. Hydrocortisone is a low-potency topical corticosteroid that acts primarily through the glucocorticoid receptor to suppress cutaneous inflammation and pruritus; the sulphated-polysaccharide vehicle is intended to provide hydrating, moisturizing, lubricating, and skin-barrier-supporting properties. In a randomized Phase I active-controlled study in patients aged 6 years or older with moderate atopic dermatitis, SNG100 showed favorable tolerability and exploratory efficacy relative to hydrocortisone 1% cream and mometasone furoate 0.1% cream.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on SNG100.